Literature DB >> 438966

Quinidine and dihydroquinidine interactions in human plasma.

C T Ueda, M C Makoid.   

Abstract

The protein-binding characteristics of dihydroquinidine, a known impurity in drug grade quinidine, in human plasma and the effects of dihydroquinidine on quinidine interactions with these plasma constituents were studied by equilibrium dialysis. In the plasma concentration range of 1.75-23.0 mg/liter, dihydroquinidine binding was similar to the binding observed with quinidine. The data suggested the presence of a single class of binding sites for both compounds in the plasma drug concentration range and samples studied. The mean values for the association constant, K, and the total concentration of binding sites, nPt, for dihydroquinidine were 4.75 +/- 0.67 X 10(4) M-1 and 5.78 +/- 0.17 x 10(-5) M, respectively. The corresponding values for quinidine were 4.78 +/- 1.00 x 10(4) M-1 and 5.65 +/- 0.48 x 10(-5) M. In the presence of 5 and 10% (of total alkaloid content) dihydroquinidine, the plasma concentration of unbound quinidine did not change significantly. At a 20% level of dihydroquinidine, however, an increase in unbound quinidine was observed (p less than 0.05). The elevations in free quinidine concentrations were directly related to the level of dihydroquinidine present. The results of this study indicate that the interactions between dihydroquinidine and quinidine for binding sites on human plasma proteins are competitive.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 438966     DOI: 10.1002/jps.2600680414

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Analysis of free drug fractions in human serum by ultrafast affinity extraction and two-dimensional affinity chromatography.

Authors:  Xiwei Zheng; Maria Podariu; Ryan Matsuda; David S Hage
Journal:  Anal Bioanal Chem       Date:  2015-10-13       Impact factor: 4.142

2.  High-throughput analysis of drug dissociation from serum proteins using affinity silica monoliths.

Authors:  Michelle J Yoo; David S Hage
Journal:  J Sep Sci       Date:  2011-06-10       Impact factor: 3.645

3.  Entrapment of alpha1-acid glycoprotein in high-performance affinity columns for drug-protein binding studies.

Authors:  Cong Bi; Abby Jackson; John Vargas-Badilla; Rong Li; Giana Rada; Jeanethe Anguizola; Erika Pfaunmiller; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-11-27       Impact factor: 3.205

4.  Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration.

Authors:  C T Ueda; B S Dzindzio
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

6.  Absorption of quinidine and dihydroquinidine in humans.

Authors:  D M Hailey; A R Lea; D M Coles; P E Heaume; W J Smith
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.